Abstract
The purpose of this study was to examine the mechanisms by which liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) stimulates monocytes to produce tumor necrosis factor (TNF) and interleukin-1 (IL-1). We have previously shown that secretion of TNF protein occurred 2–4 h following incubation of monocytes with L-MTP-PE and that this stimulation of TNF production was associated with an increase in TNF mRNA. Increased intracellular interleukin-1α (IL-1α) and IL-1β were not detected until 8 h after exposure to L-MTP-PE. To determine whether TNF played a role in the stimulation of IL-1 production by L-MTP-PE, normal human monocytes were incubated with L-MTP-PE or medium in the presence or absence of anti-TNF or anti IL-1α plus anti IL-1β. Enhanced expression of IL-1α and IL-1β mRNA was inhibited at 4 h but not 24 h when monocytes were incubated with L-MTP-PE plus anti-TNF compared with L-MTP-PE alone. By contrast, enhanced expression of TNF mRNA wasnot inhibited at any time when monocytes were incubated with L-MTP-PE and anti-IL-1α plus anti-IL-1β. These data indicate that the up-regulation of IL-1 seen in monocytes following L-MTP-PE exposure may be due in part to the production of TNF. The up-regulation of TNF, however, appears to be independent of IL-1 production.
Key words: Anti-TNF, IL-1, Liposomal MTP-PE, Monocytes, TNF
References
- 1.Bachwich PR, Chensue SW, Larrick JW, Kunkel SL. Tumor necrosis factor stimulates interleukin-1 and prostaglandin E2 production in resting macrophages. Biochem Biophys Res Commun. 1986;136:94. doi: 10.1016/0006-291x(86)90881-8. [DOI] [PubMed] [Google Scholar]
- 2.Beltoglio JH, Rimsky L, Kleinerman ES, Lachman LB. B-cell line-derived interleukin-1 is cytotoxic for melanoma cells and promotes the proliferation of an astrocytoma cell line. Lymphokine Res. 1987;6:83. [PubMed] [Google Scholar]
- 3.Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
- 4.Creaven PJ, Cowens JW, Brenner DE, Dadey BM, Han R, Huben R, Karakousis C, Frost H, LeSher D, Hanagan J, Andrejcio K, Gushman MK. Initial clinical trial of the macrophage activator muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. J Biol Response Mod. 1990;9:492. [PubMed] [Google Scholar]
- 5.DijKstra J, Mellors JW, Ryan JL, Szoka FC. Modulation of the biological activity of bacterial endotoxin by incorporation into liposomes. J Immunol. 1987;138:2663. [PubMed] [Google Scholar]
- 6.Fidler IJ, Kleinerman ES. Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol. 1984;2:937. doi: 10.1200/JCO.1984.2.8.937. [DOI] [PubMed] [Google Scholar]
- 7.Fidler IJ, Poste G. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Springer Semin Immunopathol. 1982;5:161. doi: 10.1007/BF00199794. [DOI] [PubMed] [Google Scholar]
- 8.Fidler IJ, Sone S, Fogler WE, Barnes Z. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA. 1980;78:1680. doi: 10.1073/pnas.78.3.1680. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Fidler IJ, Barnes Z, Fogler WE, Kirsh R, Gubelski P, Poste G. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res. 1982;42:496. [PubMed] [Google Scholar]
- 10.Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF, Cerami A. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J Exp Med. 1989;170:1627. doi: 10.1084/jem.170.5.1627. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Fujimaki W, Balch CM, Ross MI, Itoh K, Fidler IJ, Kleinerman ES. Pilot study of liposomal muramyl tripeptide in melanoma patients: cytokine production and activation of monocytes and lymphocytes. Proc Am Assoc Cancer Res. 1992;33:331. [Google Scholar]
- 12.Kaushansky K, Broudy VC, Harlan JM, Adamson JW. Tumor necrosis factor-α and tumor necrosis factor-β (lymphotoxin) stimulate the production of granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor and IL-1 in vivo. J Immunol. 1988;141:3410. [PubMed] [Google Scholar]
- 13.Kaye J, Porcelli S, Tite J, Jones B, Janeway CA. Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells. J Exp Med. 1983;158:836. doi: 10.1084/jem.158.3.836. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res. 1983;43:2010. [PubMed] [Google Scholar]
- 15.Kleinerman ES, Schroit AJ, Fogler WE, Fidler IJ. Tumoricidal activity of human monocytes activated in vitro by free and encapsulated human lymphokines. J Clin Invest. 1983;72:304. doi: 10.1172/JCI110970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Kleinerman ES, Knowles RD, Blick MB, Zwelling LA. Lithium chloride stimulates human monocytes to secrete tumor necrosis factor/cachectin. J Leukoc Biol. 1989;46:484. doi: 10.1002/jlb.46.5.484. [DOI] [PubMed] [Google Scholar]
- 17.Kleinerman ES, Jia S-F, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992;10:1310. doi: 10.1200/JCO.1992.10.8.1310. [DOI] [PubMed] [Google Scholar]
- 18.Lachman LB, Dinarelli CA, Llansa ND, Fidler IJ. Natural and recombinant human interleukin-1β is cytotoxic for human melanoma cells. J Immunol. 1986;136:3098. [PubMed] [Google Scholar]
- 19.Liebes L, Walsh CM, Chachoua A, Oratz R, Richards D, Hochster H, Peace D, Marino D, Alba S, LeSher D, Blum RH, Vilcek J. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma. INCI. 1992;84:694. doi: 10.1093/jnci/84.9.694. [DOI] [PubMed] [Google Scholar]
- 20.Lovett D, Kozan B, Hadam M, Resch K, Gemsa D. Macrophage cytotoxicity: interleukin-1 as a mediator of tumor cytostasis. J Immunol. 1986;136:340–347. [PubMed] [Google Scholar]
- 21.MacEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, Roush JK, Howard PE. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. JNCI. 1989;81:935. doi: 10.1093/jnci/81.12.935. [DOI] [PubMed] [Google Scholar]
- 22.Maeda M, Knowles RD, Kleinerman ES. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte to produce tumor necrosis factor and interleukin-1 in vitro. Cancer Commun. 1991;3:313. doi: 10.3727/095535491820873740. [DOI] [PubMed] [Google Scholar]
- 23.Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lumki LM, Rosenblum MG, Frost H, Gutterman JU, Fidler IJ, Krakoff I. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol. 1989;7:1915. doi: 10.1200/JCO.1989.7.12.1915. [DOI] [PubMed] [Google Scholar]
- 24.Old LJ. Tumor necrosis factor (TNF) Science. 1985;230:630. doi: 10.1126/science.2413547. [DOI] [PubMed] [Google Scholar]
- 25.Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ. Human interleukin-1 is a cytocidal factor for several tumor cell lines. J Immunol. 1985;135:3962. [PubMed] [Google Scholar]
- 26.Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 1982;42:1412. [PubMed] [Google Scholar]
- 27.Smith DM, Lachides GA, Epstein LB. Coordinated induction of autocrine tumor necrosis factor and interleukin-1 in normal human monocytes and the implications for monocyte-mediated cytotoxicity. Cancer Res. 1990;50:3146. [PubMed] [Google Scholar]
- 28.Sugarman BJ, Aggarwal BB, Hass PE, Figari MA, Palladino MA, Jr, Shepard HM. Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science. 1985;230:943. doi: 10.1126/science.3933111. [DOI] [PubMed] [Google Scholar]
- 29.Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, Schreiber H. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci USA. 1986;83:5233. doi: 10.1073/pnas.83.14.5233. [DOI] [PMC free article] [PubMed] [Google Scholar]
